ReviewInternational journal of molecular sciences2020
Current Molecular Markers of Melanoma and Treatment Targets.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 78 citations in OpenAlex.
- MKLNID: Identifying Melanoma-related Pathogenic Genes Through Multiple Kernel Learning and Network Impulsive Dynamics.Interdisciplinary sciences, computational life sciences · 2026Article
- Silencing myeloid cell leukemia-1 improves apoptotic and ferroptotic responses in melanoma.European journal of medical research · 2026Article
- Synergistic inhibition of metastatic melanoma by carvacrol and chloroquine: an in vitro and in silico investigation of apoptosis and molecular targets.Medical oncology (Northwood, London, England) · 2026Article
- Melanoma treatment in the era of nanotechnology and precision medicine.Journal of nanobiotechnology · 2025Review
- CircSipa1l1 modulates melanoma cell differentiation by activating the IGF2BP1-ARHGDIB axis and ERK signaling pathway.Journal of translational medicine · 2025Article
- Angiogenesis-Related Genes Predict Outcomes and Immune Traits in Skin Melanoma.International journal of molecular sciences · 2025Article
- Aggressive nodular melanoma: case report with an unusual BRAF mutation.Molecular biology reports · 2025Article
- A novel necroptosis related prognostic signature for skin cutaneous melanoma based on transcriptome and single cell sequencing analysis.Scientific reports · 2025Article
- Paradigm of biomarkers in metastatic melanoma (Review).Oncology letters · 2025Review
- Glycolysis regulated exosomal LINC01214 inhibited CD8Non-coding RNA research · 2025Article
- Amelanotic Melanoma-Biochemical and Molecular Induction Pathways.International journal of molecular sciences · 2024Review
- Review
- Melanoma Management: Exploring Staging, Prognosis, and Treatment Innovations.International journal of molecular sciences · 2024Review
- 5-Methylcytosine immunohistochemistry for predicting cutaneous melanoma prognosis.Scientific reports · 2024Article
- Fer-1 like family member 4 pseudogene: novel potential diagnostic and prognostic biomarker for cutaneous melanoma.EXCLI journal · 2024Article
- Atypical primary malignant melanoma originating in the spinal canal: A case report and literature review.Oncology letters · 2023Article
- Safety and rapid response of dabrafenib and trametinib therapy during hyperbilirubinemia in metastatic melanoma.Frontiers in oncology · 2023Article
- Causal association between serum 25-Hydroxyvitamin D levels and cutaneous melanoma: a two-sample Mendelian randomization study.Frontiers in oncology · 2023Article
- Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma.Oncology letters · 2023Article
- Cutaneous melanocytic tumor with CRTC1::TRIM11 fusion and prominent epidermal involvement: A case report.Journal of cutaneous pathology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Melanoma is a deadly skin cancer that becomes especially difficult to treat after it metastasizes. Timely identification of melanoma is critical for effective therapy, but histopathologic diagnosis can frequently pose a significant challenge to this goal. Therefore, auxiliary diagnostic tools are imperative to facilitating prompt recognition of malignant lesions. Melanoma develops as result of a number of genetic mutations, with UV radiation often acting as a mutagenic risk factor. Novel methods of genetic testing have improved detection of these molecular alterations, which subsequently revealed important information for diagnosis and prognosis. Rapid detection of genetic alterations is also significant for choosing appropriate treatment and developing targeted therapies for melanoma. This review will delve into the understanding of various mutations and the implications they may pose for clinical decision making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.